by | Jun 26, 2024 | Publications
Br J Clin Pharmacol. 2024 Jun 23. doi: 10.1111/bcp.16133. Online ahead of print. ABSTRACT AIMS: To evaluate relationships between plasma concentrations of belantamab mafodotin, total monoclonal antibody, and its payload and changes in electrocardiogram (ECG)...
by | Jun 26, 2024 | Publications
Ann Acad Med Singap. 2023 Nov 29;52(11):590-600. doi: 10.47102/annals-acadmedsg.2022414. ABSTRACT INTRODUCTION: This study aimed to evaluate the clinical utility of positron emission tomography/magnetic resonance imaging (PET/MRI), especially in comparison with...
by | Jun 26, 2024 | Publications
Ann Acad Med Singap. 2023 Nov 29;52(11):601-624. doi: 10.47102/annals-acadmedsg.2023101. ABSTRACT AL amyloidosis is the most common form of systemic amyloidosis. However, the non-specific nature of presenting symptoms requires the need for a heightened clinical...
by | Jun 26, 2024 | Publications
Expert Rev Hematol. 2024 Jun 26:1-18. doi: 10.1080/17474086.2024.2370552. Online ahead of print. ABSTRACT INTRODUCTION: Chimeric Antigen Receptor (CAR) T-cells and Bispecific Antibodies (BsAb) are the leading platforms for redirecting the immune system against cells...
by | Jun 26, 2024 | Publications
Iran J Public Health. 2024 Mar;53(3):568-576. doi: 10.18502/ijph.v53i3.15137. ABSTRACT Multiple Myeloma (MM) is a neoplastic hematologic disorder caused by the excessive proliferation of plasma cells and leads to bone lesions, anemia, and kidney failure. No definite...
by | Jun 26, 2024 | Publications
Front Oncol. 2024 Jun 11;14:1365460. doi: 10.3389/fonc.2024.1365460. eCollection 2024. ABSTRACT BACKGROUND: Multiple myeloma (MM) exhibits considerable heterogeneity in treatment responses and survival rates, even when standardized care is administered. Ongoing...
